{
    "clinical_study": {
        "@rank": "13344", 
        "arm_group": {
            "arm_group_label": "Idarubicin(IDA)", 
            "arm_group_type": "Active Comparator", 
            "description": "philadelphia negative high -risk ALL : Induction therapy: IDA(6mg/m2/time) one time for each week,altogether 3 times"
        }, 
        "brief_summary": {
            "textblock": "The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly\n      in recent decades and expected cure rates now exceed 85%. In recent years, Tyrosine Kinase\n      Inhibitor(TKI) has improved outcome of Philadelphia chromosome positive (Ph+)ALL . But in\n      some high risk groups, The prognosis of patients is still very bad and the relapse rate is\n      high. Clearly, new therapies are urgently needed to prevent and /or treat relapsed ALL."
        }, 
        "brief_title": "Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Childhood Acute Lymphoblastic Leukemia", 
            "Philadelphia Chromosome, Ph^1^, Absent", 
            "B-cell Childhood Acute Lymphoblastic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Philadelphia Chromosome"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. The prognosis of childhood acute lymphoblastic leukemia(ALL) has been increased.\n\n        2. Tyrosine Kinase Inhibitor(TKI) has improved  Philadelphia chromosome positive (Ph+)ALL\n           treatment outcome.\n\n        3. The prognosis of high-risk childhood ALL except for Philadelphia chromosome positive\n           (Ph+)ALL is very bad."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Children with high-risk ALL Children lower than 18years old\n\n        Exclusion Criteria:\n\n        Bcr/Abl(+) Children with middle-risk or standard-risk ALL"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990807", 
            "org_study_id": "CCALL2012"
        }, 
        "intervention": {
            "arm_group_label": "Idarubicin(IDA)", 
            "description": "6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.", 
            "intervention_name": "Idarubicin(IDA)", 
            "intervention_type": "Drug", 
            "other_name": "darubicin, IDA, Demethoxydaunor Ubicin"
        }, 
        "intervention_browse": {
            "mesh_term": "Idarubicin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "high risk", 
            "Philadelphia Chromosome absent", 
            "Childhood acute lymphoblastic leukemia"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "email": "xfzhu1981@126.com", 
                "last_name": "Xiaofan Zhu, MD", 
                "phone": "+86-22-23909001"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300020"
                }, 
                "name": "Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Scienses"
            }, 
            "investigator": {
                "last_name": "Xiaofan Zhu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine", 
        "other_outcome": {
            "measure": "infection rate", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "overall_contact": {
            "email": "xfzhu1981@126.com", 
            "last_name": "Xiaofan Zhu, MD", 
            "phone": "+86-22-23909001"
        }, 
        "overall_official": {
            "affiliation": "Chinese Academy of Medical Sciences", 
            "last_name": "Xiaofan Zhu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The event free survival of high risk ALL", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990807"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Xiaofan Zhu", 
            "investigator_title": "chief physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The relapsed rate, death, overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}